containing mRNA, miRNA and angiogenic proteins. These microvesicles are taken up by normal host cells, such as brain microvascular endothelial cells. By incorporating an mRNA for a reporter protein into these microvesicles, we demonstrate that messages delivered by microvesicles are translated by recipient cells. These microvesicles are also enriched in angiogenic proteins and stimulate tubule formation by endothelial cells. Tumour-derived microvesicles therefore serve as a means of delivering genetic information and proteins to recipient cells in the tumour environment. Glioblastoma microvesicles also stimulated proliferation of a human glioma cell line, indicating a self-promoting aspect. Messenger RNA mutant/variants and miRNAs characteristic of gliomas could be detected in serum microvesicles of glioblastoma patients. The tumour-specific EGFRvIII was detected in serum microvesicles from 7 out of 25 glioblastoma patients. Thus, tumour-derived microvesicles may provide diagnostic information and aid in therapeutic decisions for cancer patients through a blood test.
1
. These and many other tumours have a remarkable ability to mould their stromal environment to their own advantage. Tumour cells alter surrounding normal cells to facilitate tumour cell growth, invasion, chemoresistance, immune evasion and metastasis [2] [3] [4] . The tumour cells also hijack the normal vasculature and stimulate rapid formation of new blood vessels to supply nutrition to the tumour 5 . Although the immune system can initially suppress tumour growth, it is often progressively blunted by tumour activation of immunosuppressive pathways 6 . Recent studies show the importance of communication between tumour cells and their environment through shedding of membrane microvesicles, which can fuse to cells in the vicinity 7 
.
Microvesicles are 30-100 nm in diameter and are shed from many different cell types under both normal and pathological conditions 8 . These exosomes can be formed through inward budding of endosomal membranes, giving rise to intracellular multivesicular bodies (MVB) that later fuse with the plasma membrane, releasing the exosomes to the exterior 8, 9 . They can also be shed directly by outward budding of the plasma membrane, as shown for Jurkat T-cells 10 . Microvesicles in Drosophila melanogaster, termed argosomes, contain morphogens, such as Wingless protein, and move throughout the imaginal disc epithelium in the developing embryos 11 . Microvesicles found in semen, known as prostasomes, can promote sperm motility, stabilize the acrosome reaction, facilitate immunosuppression and inhibit angiogenesis 12 . On the other hand, prostasomes released by malignant prostate cells promote angiogenesis. It has been shown that microvesicles can transfer some of their contents to other cell types [13] [14] [15] [16] . The content of microvesicles and their biological function depend on the cell of origin. Microvesicles derived from B-cells and dendritic cells have potent immunostimulatory and antitumour effects in vivo and have been used as antitumour vaccines 17 . Microvesicles derived from dendritic cells contain co-stimulatory proteins necessary for T-cell activation, whereas most microvesicles derived from tumour cells do not. Instead, they act to suppress the immune response and accelerate tumour growth and invasiveness [18] [19] [20] [21] . Breast cancer microvesicles stimulate angiogenesis, and platelet-derived microvesicles promote tumour progression and metastasis of lung cancer cells 22, 23 . Human glioblastoma tissues were obtained from surgical resections. Tumour cells were dissociated and cultured as monolayers in medium containing fetal bovine serum depleted of microvesicles (dFBS). Cultured primary cells obtained from three glioblastoma tumours were found to produce microvesicles at early and later passages (1-15 passages). Tumour cells were covered with microvesicles varying in size from about 50-500 nm (Fig. 1a, b) . The microvesicles contained RNA and protein in a ratio of approximately 1:80. To evaluate whether the RNA was contained inside the microvesicles, they were either exposed to RNase A or left untreated before RNA extraction (Fig. 1c) . There was always a decrease of less than 7% in RNA content following RNase treatment. Thus, it appears that almost all of the RNA is contained within the vesicles and is thereby protected from external RNases by the surrounding membrane. Bioanalysis of RNA from microvesicles and their donor cells revealed that the microvesicles contain a broad range of RNA sizes, consistent with a variety of mRNAs and miRNAs, but lack the ribosomal RNA peaks characteristic of cellular RNA (Fig. 1d, e) .
Microarray analysis of mRNA populations in microvesicles and their donor glioblastoma cells was performed using the Agilent 44K whole genome microarray. Approximately 22,000 gene transcripts were found in the cells and 27,000 transcripts in the microvesicles (detected at levels well above background, 99% confidence interval) on both arrays. Approximately 4,700 different mRNAs were detected exclusively in microvesicles on both arrays, indicating a selective enrichment process within the microvesicles (Supplementary Information, Table S1 ). Consistent with this, there was a poor overall correlation in levels of mRNAs in the cells, compared with microvesicles from two tumour preparations (Fig. 2a, b) , supporting selective enrichment of some cellular mRNAs in microvesicles. In contrast, comparison of the levels of specific mRNAs in different preparations of donor cells or of microvesicles showed a strong correlation, indicating a consistent distribution within these distinct cellular compartments (Fig. 2c, d ). We found 3,426 transcripts differentially distributed more than 5-fold (P < 0.01). Of these, 2,238 transcripts were enriched (up to 380-fold) and 1,188 transcripts were less abundant than in the cells (up to 90-fold; Fig. 2e ). The intensities and ratios of all gene transcripts are shown in Supplementary Information, Table S2 . Ontologies of mRNA transcripts enriched or reduced more than 10-fold are listed in Supplementary Information , Table S3 .
The mRNA transcripts that are highly enriched in microvesicles, compared with cells, are not always the most abundant in the microvesicles. The most abundant transcripts would be more likely to generate an effect in the recipient cell upon delivery. The 500 most abundant mRNA transcripts in microvesicles were divided into different biological processes on the basis of their ontology descriptions (Fig. 2f) . Glioblastoma microvesicle mRNAs belonging to ontologies such as angiogenesis, cell proliferation, immune response, cell migration and histone modification were plotted to compare their levels and contribution to the mRNA spectrum (Fig. 2g) . These ontologies were selected as they represent functions that could be involved in remodelling the tumour stroma and enhancing tumour growth. All five ontologies contained mRNA with very high expression levels, compared with the median signal intensity level of the array.
Mature miRNA in microvesicles and donor cells were detected using quantitative miRNA reverse transcription PCR. A subset of 11 miRNAs known to be abundant in gliomas (A.M.K., unpublished data) was readily detected in donor cells and microvesicles from two different primary glioblastomas (GBM 1 and GBM 2; Fig. 2h ). The levels were generally lower in microvesicles per µg total RNA than in parental cells (10%, corresponding to approximate 3 Ct values), but correlated well with the tumour profile.
Glioblastoma microvesicles labelled with the fluorescent dye PKH67 were incubated with human brain microvascular endothelial cells (HBMVEC) in culture. The PKH67-labelled microvesicles were internalized into endosome-like structures by brain endothelial cells (Fig. 3a) . Similar results were obtained when adding the fluorescently labelled microvesicles to primary glioblastoma cells (data not shown).
To determine whether the mRNA delivered by glioblastoma-derived microvesicles could be expressed in recipient cells, glioblastoma cells were first transduced with a lentivirus vector encoding a secreted luciferase from Gaussia (Gluc) 24 , and microvesicles produced by them were purified from the conditioned medium. RT-PCR analysis showed that the mRNA for Gluc (555-bp product), as well as GAPDH (226-bp product), were present in the microvesicles (Fig. 3b) released into the medium by these endothelial cells was monitored over time ( Fig. 3c ). Gluc activity produced by recipient cells showed a continuing increase over 24 h, supporting ongoing translation of the Gluc mRNA. This method shows that mRNA incorporated into the tumour microvesicles can be delivered into recipient normal cells and generate a functional protein.
Nucleic acids are of high value as biomarkers because of highly sensitive PCR detection. We evaluated whether the RNA in microvesicles could be used as biomarkers for glioblastoma tumours. The epidermal growth factor receptor (EGFR) mRNA is particularly interesting as expression of the EGFRvIII mutant/variant is specific to some tumours and defines a clinical subtype of glioma 25 . We used a nested RT-PCR to determine whether EGFRvIII mRNA was found in resected glioma tissue and compared the result with microvesicles purified from a frozen serum sample from the same patient. The samples were coded and PCR was performed in a blinded fashion. Fourteen of the 30 tumour samples (47%) contained the EGFRvIII transcript, which is consistent with the percentage of glioblastomas found to contain this mutant message in other studies 26 . EGFRvIII could be amplified from microvesicles in seven of the 25 patients (28%) from whom serum was drawn around the time of surgery (Table 1 ; Supplementary Information, Fig. S1 ). Interestingly, two patients with EGFRvIII-negative tumour samples were positive for serum microvesicles, supporting heterogeneous foci of EGFRvIII expression in the glioma tumour. EGFRvIII message was not detected in five serum samples drawn two weeks after extensive resection of the tumour, with four corresponding to EGFRvIII-positive tumours, consistent with this tumour being the source of microvesicles. Furthermore, EGFRvIII was not found in serum microvesicles from 30 normal control individuals ( Supplementary Information, Fig. S2 ). We also found that miRNA-21, known to be overexpressed in glioblastoma tumours 27 , was elevated in serum microvesicles from these patients, compared with controls ( Supplementary Information, Fig. S3 ). Identification of tumour-specific RNAs in serum microvesicles thus provides a window into somatic mutations and changes in gene expression in tumour cells. 
l e t t e r s
To determine whether glioblastoma microvesicles could contribute to angiogenesis, we used an in vitro angiogenesis assay. HBMVECs were cultured in Matrigel-coated plates containing endothelial basal medium (EBM), EBM-supplemented purified glioblastoma microvesicles or EBM plus angiogenic growth factors (EGM). In the presence of microvesicles, tubule length of HBMVECs doubled within 16 h. This was comparable to the effects of angiogenic factors (Fig. 4a) and supports a role for glioblastoma-derived microvesicles in initiating angiogenesis in brain endothelial cells.
To further characterize the angiogenic capability of microvesicles, we determined the levels of angiogenic proteins in microvesicles and compared them with levels in glioblastoma donor cells using a human angiogenesis antibody array (Fig. 4b) . Seven of the 19 angiogenic proteins were readily detected in the microvesicles, six (angiogenin, IL-6, IL-8, TIMP-1, VEGF and TIMP-2) were present at higher levels on a total protein basis than in glioblastoma cells (Fig. 4c) . The three angiogenic proteins most enriched were angiogenin, IL-6 and IL-8, all of which have been implicated in glioma angiogenesis and increased malignancy [28] [29] [30] . This indicates that the angiogenic effect of microvesicles is mediated at least in part by angiogenic proteins.
Human U87 glioma cells were incubated in normal growth medium or medium supplemented with microvesicles isolated from primary glioblastoma cells. After three days, there was a 5-fold increase in the number of untreated U87 cells, whereas cells supplemented with microvesicle increased 8-fold ( Supplementary Information, Fig. S4 ). Thus, glioblastoma microvesicles seem to stimulate proliferation of a glioma cell line.
These results are consistent with the ability of microvesicles shed from tumour cells to serve as a means by which tumours can manipulate their environment, making it more favourable for tumour growth and invasion. In this study we have documented the abundant shedding of microvesicles by primary human glioblastoma cells. We characterized mRNA and miRNA profiles present in these cells and microvesicles and showed that particular mRNAs are highly enriched in these microvesicles, compared with donor cells. In fact, more mRNA transcripts were detected at levels well above background in microvesicles as compared with cells. This difference could be due in part to the large amount of ribosomal RNA in the cells, compared with microvesicles, increasing the relative amount of mRNA per µg of total RNA in the microvesicles. Ontology analysis showed that a number of mRNA transcripts associated with cell migration, angiogenesis, cell proliferation, immune response and histone modification are present at high levels in the microvesicles. The miRNAs in microvesicles seemed to parallel their distribution in the glioblastoma cells. We have shown that glioblastoma microvesicles can enter HBMVECs and translate a reporter mRNA carried by the microvesicles. This suggests that the tumour-derived microvesicles can modify the surrounding normal cells by changing their translational profile. Further, we have shown that glioblastoma microvesicles can stimulate an angiogenic phenotype in normal brain endothelial cells and can stimulate the proliferation of other glioma cells. In addition to the potential role of mRNAs in these processes, microvesicles also contain a number of angiogenic proteins, such as angiogenin, FGFα, IL-6, IL-8, TIMP-1, VEGF and TIMP-2. Presumably, most of these interact with cognate receptors on the surface of endothelial cells to promote angiogenesis, and may require extracellular lysis of the microvesicles, with release of proteins contained within them. It has been proposed that the acidic environment in established tumours can promote lysis of some of the microvesicles, making intravesicular proteins bioavailable 31 . On the other hand, angiogenic proteins, such as angiogenin, require transportation across the membrane to exert their biological effect 32 , which could be facilitated by the microvesicles. Tumour microvesicles thus act as a multicomponent delivery vehicle for mRNA, miRNA and proteins, to communicate genetic information as well as signalling proteins to cells in their vicinity.
This study presents a thorough analysis of mRNAs that are enriched in the microvesicles versus donor cells, suggesting that there may be a cellular mechanism for localizing these messages into microvesicles, possibly through a zip code in the 3´-UTR, as described for mRNAs translated in specific cellular locations, for example, β-actin 33 . The conformation of the mRNAs in the microvesicles is not known, but they may be present as ribonuclear particles (RNPs) 34 . Evidence suggests that retroviruses, such as HIV, can use the endogenous microvesicle machinery for budding and generation of new virus particles 10 . Interestingly, several endogenous retroviral RNA sequences were found to be highly enriched in the microvesicles (Supplementary Information, Table S2 ).
The RNA found in the microvesicles contains a 'snapshot' of a substantial array of the cellular transcriptome at any given time. Among the mRNAs found in glioblastoma-derived microvesicles, EGFR mRNA is of particular interest as the EGFRvIII mutant splice variant is found specifically in many glioblastomas 26 . Using nested RT-PCR, we were able to detect the EGFRvIII message in tumour biopsies and serum microvesicles from glioblastoma patients, but not in any of 30 normal control serum samples. We showed that brain tumours release microvesicles into the bloodstream and that we can genetically type EGFRvIII status of glioblastoma tumours by nested RT-PCR of RNA in microvesicles isolated from a small amount of patient serum, compared with other methods that require invasive brain surgery. The sensitivity of this assay may depend on factors including tumour size, tumour location and serum volume, as well as the method of RNA extraction, cDNA conversion and PCR used. Information about EGFRvIII status of glioblastoma patients could be useful in the ongoing EGFRvIII vaccine trial and other therapeutic clinical trials 35 . One study showed that EGFRvIII-positive gliomas respond 50 times better than EGFRvIII-negative cells to treatment with EGFR inhibitors, such as erlotinib or gefitinib 36 . Thus, we propose a new way of looking at molecular determinants of cancer, including, but not limited to, EGFRvIII, by isolating microvesicles from serum and extracting the RNA for profiling and detection of mutations, splice variants and levels of mRNAs and miRNAs characteristic of tumour formation, progression and response to therapy.
Microvesicles may provide a means of detecting evolving genetic changes relative to tumour progression using serum samples drawn over time, presumably regardless of the cancer type or where the tumour foci are situated in the individual. Further, knowledge of tumour genotype and phenotype gained through microvesicle analysis may help in designing tailored therapies to curtail tumour growth. Finally, microvesicles may prove useful as a delivery vehicle for therapeutic RNAs and proteins.
METHODS
Collection of tumour samples and serum from glioblastoma patients. For cell culture, brain tumour specimens from patients diagnosed by a neuropathologist as glioblastoma multiforme were taken directly from surgery and placed in cold sterile neurobasal medium (Invitrogen). The specimens were dissociated into single cells within 1 h of surgery using a neural tissue dissociation kit (Miltenyi Biotech) and plated in DMEM containing 5% dFBS (prepared by ultracentrifugation at 110,000g for 16 h to remove bovine microvesicles) and supplemented with penicillin-streptomycin (10 IU ml -1 and 10 µg ml -1 , respectively, Sigma-Aldrich). Microvesicle isolation. Glioblastoma cells at passage 1-15 were cultured in microvesicle-free medium (DMEM containing 5% dFBS) and conditioned medium from 4 × 10 7 cells was collected after 48 h. Microvesicles were purified by differential centrifugation 15 . In brief, glioblastoma-conditioned medium was centrifuged for 10 min at 300g to eliminate cell contamination. Supernatants were further centrifuged for 20 min at 16,500g and filtered through a 0.22 µm filter. Microvesicles were pelleted by ultracentrifugation at 110,000g for 70 min. The microvesicle pellets were washed in 13 ml PBS, pelleted again and resuspended in PBS. Microvesicles were measured for their protein content using the DC protein assay (Bio-Rad). Serum microvesicles from healthy controls and glioblastoma patients were diluted to 13 ml in PBS and sterile-filtered before centrifugation.
RNA isolation.
To evaluate whether RNA was present inside the microvesicles, RNase A (Fermentas) was added to suspensions of microvesicles at a final concentration of 100 µg ml -1 and incubated for 15 min at 37 °C. Total RNA was then purified using the MirVana RNA isolation kit (Ambion) according to the manufacturer's protocol. The RNA was quantified using a nanodrop ND-1000 (Thermo Fischer Scientific). Snap-frozen tumour biopsies were thawed on RNAlater ICE (Ambion) according to manufacturer's recommendation, followed by RNA extraction using the MirVana RNA isolation kit.
Microarray analysis.
The microarray experiments were performed by Miltenyi Biotech (Auburn) using the Agilent whole human genome microarray, 4×44K, two-colour array. The array was performed on two different RNA preparations from primary glioblastoma cells and their microvesicles. The data were analysed using the GeneSifter software (Vizxlabs). The Intersector software (Vizxlabs) was used to extract genes readily detected on both arrays.
Quantitative miRNA RT-PCR. Total RNA was isolated using the mirVana RNA isolation kit. Total RNA (30 ng) was converted into cDNA using specific miRprimers (Applied Biosystems) and further amplified according to the manufacturer's protocol.
HBMVEC in vitro angiogenesis assay. HBMVECs (30,000; Cell Systems, catalogue no. ACBRI-376) were cultured on Matrigel-coated wells in a 24-well plate in basal medium (Lonza Biologics) only, or supplemented with glioblastoma microvesicles (7 µg per well) or a cocktail of angiogenic factors (EGM; hydrocortisone, EGF, FGF, VEGF, IGF, ascorbic acid, FBS and heparin; Singlequots from Lonza). Tubule formation was measured after 16 h and analysed with the ImageJ software (NIH).
Gluc mRNA translation assay. Primary human glioblastoma cells were infected with a self-inactivating lentivirus vector expressing secreted Gluc under a cytomegalovirus promoter 37 to achieve an infection efficiency of more than 95%. The cells were stably transduced and microvesicles generated during the subsequent passages (2-10) were isolated and purified as above. Microvesicles (50 µg) were added to 50,000 HBMVECs and incubated for 24 h. Gluc activity in the supernatant was measured directly after microvesicle addition (0 h), and 15 and 24 h later, then normalized to Gluc activity in the microvesicles. The results are presented as the mean ± s.e.m. (n = 4).
PKH67-labelled microvesicles.
Purified glioblastoma microvesicles were labelled with PKH67 green fluorescent labelling kit (Sigma-Aldrich) as described previously 21 . The labelled microvesicles were incubated with HBMVEC in culture (5 µg per 50,000 cells). Microvesicles were allowed to bind for 20 min at 4 ºC and cells were then washed and incubated at 37 ºC for 1 h.
RT-PCR and nested PCR. RNA was extracted using the MirVana RNA isolation kit. RNA was converted to cDNA using the Omniscript RT kit (if starting material was >50 ng) or Sensiscript RT kit (if starting material was <50 ng) (Qiagen) using a mixture of oligonucleotides and random hexamer primer according to the manufacturer's recommendation. The following PCR primers were used: GAPDH primers, forward: 5´-GAA GGT GAA GGT CGG AGT C-3´, reverse: 5´-TCA-GAA GAT GGT GAT GGG ATT TC-3´; EGFR/ EGFRvIII PCR1, forward 5´-CCAGTATTGATCGGGAGAGC-3´, reverse 5´-TCAGAATATCCAGTTCCTGTGG-3´, EGFR/EGFRvIII PCR2, forward 5´-ATG CGA CCC TCC GGG ACG-3´, reverse 5´-GAG TAT GTG TGA AGG AGT-3´. The Gluc primers have been described previously 24 . The PCR protocol was: 3 min at 94 ºC; 45 s at 94 ºC, 45 s at 60 ºC, 2 min at 72 ºC for 35 cycles; 72 ºC 7 min.
Angiogenesis antibody array. Total protein (1 mg) from primary glioblastoma cells or purified microvesicles isolated from the same cells were lysed in lysis buffer (Promega) and then added to the human angiogenesis antibody array (Panomics), according to manufacturer's recommendations. The arrays were scanned and analysed with the ImageJ software (NIH).
Statistics. Statistical analyses were performed using Students t-test.
Accession number. The microarray data have been deposited in NCBI's Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo) and are accessible through GEO series accession number GSE13470.
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Figure S1 Nested RT PCR was used to detect EGFRvIII mRNA in the tumor sample and the corresponding serum exosomes. The wild type EGFR PCR product appears as a band at 1153 bp and that of EGFRvIII at 352 bp. RT PCR of GAPDH mRNA was included as a positive control (226 bp). EGFRvIII is indicated with an asterisk. Patient 11, 12 and 14 showed only a weak amplification of EGFRvIII in the tumor sample, but it was evident when more samples were loaded.
Figure S2
Nested RT PCR of EGFRvIII was performed on microvesicles from 30 normal control serums. EGFRvIII (352 bp) was never found in the normal control serums. PCR of GAPDH (226 bp) was included as a control.
Figure S3
Quantitative RT PCR was used to measure the levels of miR21 in exosomes from serum of glioblastoma patients or normal controls. Glioblastoma serum showed a 5.4 reduction of the Ct-value, corresponding to approximately 40-fold increase of miR21 (2 --∆Ct ). The miR21 levels was normalized to GAPDH in each sample (n=3).
Figure S4
Microvesicles isolated from primary glioblastoma cells promote proliferation of the U87 glioblastoma cell line. 100,000 U87 cells were seeded in wells of a 24 well plate and allowed to grow for three days in (a) normal growth medium (DMEM-5% FBS) or (b) normal growth medium supplemented with 125 µg microvesicles (MV). (c) After three days, the non-supplemented cells had expanded to 480,000 cells, whereas the microvesicle-supplemented cells were 810,000 cells. The result is presented as the mean ± SEM (n=6).
